Scott Lippman, M.D.
Scott M. Lippman, M.D., is director of Moores Cancer Center at UC San Diego Health, professor of Medicine at UC San Diego School of Medicine, senior associate dean and associate vice chancellor for Cancer Research and Care and holds the Chugai Pharmaceutical Chair in Cancer. He is also an adjunct…...
Fei Shen, Ph.D.
Fei is an Investment Director in the Boehringer Ingelheim Corporate Venture Fund. She joined the Boehringer Ingelheim Venture Fund in 2020 and is located in Boston, MA. Fei received her Ph.D. in Neuropharmacology from Loyola University Chicago Stritch School of Medicine and a B.Sc in Biochemistry from East China University…...
Aleksandra Filipovic, M.D., Ph.D.
Aleksandra Filipovic MD, PhD, is head of oncology at PureTech, where she manages Oncology Asset Sourcing, review of oncology/ immuno oncology technologies and platforms from academia world-wide as well as biotech assets and pipelines amenable for commercialization and partnership. She is also responsible for pre-clinical and clinical development of therapeutics,…...
Dimitra Georganopoulou, Ph.D.
Dimitra currently serves on the Innovation Faculty of MIT linQ CATALYST. In this capaticy she mentors and guides innovators to accelerate and heighten the impact of their solutions on serious health and medical challenges. Dimitra was responsible for assessing and promoting inventions generated at Northwestern University as the Innovation and…...
Alfred Slanetz, Ph.D.
Dr. Alfred Slanetz is the founder, president, and chief executive officer of Geneius and has been since its incorporation. He also has served as a director on Geneius’s board since its incorporation in 2012. Geneius, an immuno-oncology start-up, is researching ways to help cancer patients’ immune systems detect and attack…...
Will Liu, Ph.D.
Dr. Will Liu is a Partner of Eight Roads Ventures China, specializing in healthcare investment. Dr. Liu has twenty years of experience in the pharmaceutical and biotech industries, both in R&D and in business development. Prior to joining Eight Roads, he held several positions of business development in multinational pharmaceutical…...
Brian Leyland-Jones, MBBS, Ph.D.
Brian Leyland-Jones, BSc (Ist class Hons), MBBS, PhD, FRACP, FRCPC is the Chief Medical Officer of AIM-HI Accelerator Fund and the N OF 1 Mission, CSO of The Darwin Foundation, collectively devoted to the implementation of prevention and cure of malignancy globally. He sits on several national and international boards…...
Pamela Garzone, Ph.D.
Pamela Garzone, Ph.D., joined Calibr as chief medical officer in May 2019, bringing decades of clinical research experience spanning large pharmaceutical companies, biotech startups and academia. She has been responsible for more than 20 successful Investigational New Drug (IND) submissions in her industrial career. Pamela most recently served as a…...
Raju Kucherlapati, Ph.D.
Since 2001 Dr. Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and was the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG). Dr. Kucherlapati received his Ph.D. from the University of Illinois at Urbana…...